Alpha-synuclein aggregation in Parkinson's disease

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Alpha-synuclein (α-Syn) aggregation is a key factor in Parkinson's disease pathogenesis.
• Misfolded α-Syn forms toxic oligomers and fibrils, leading to Lewy bodies.
• Factors like genetics, protein interactions, and environmental toxins contribute to α-Syn pathology.

Purpose of the Study:

• To review recent therapeutic strategies for Parkinson's disease.
• To explore the role of α-Syn aggregation in disease development.
• To highlight novel compounds targeting α-Syn.

Main Methods:

• Literature review of recent studies on Parkinson's disease and α-Syn.
• Analysis of therapeutic strategies targeting α-Syn aggregation.
• Discussion of natural and synthetic compounds with inhibitory effects.

Main Results:

• Several natural compounds, like Skullcapflavone II, inhibit α-Syn fibrillation.
• Synthetic compounds, including triazole phenylamides and phenethylamides, also reduce α-Syn aggregation.
• These compounds offer potential therapeutic benefits by reducing α-Syn cytotoxicity.

Conclusions:

• Targeting α-Syn aggregation is a promising therapeutic avenue for Parkinson's disease.
• Natural and synthetic compounds demonstrate efficacy in inhibiting α-Syn pathology.
• Further research into these compounds could lead to effective Parkinson's disease treatments.